Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer
Ontology highlight
ABSTRACT: The purpose of this study is to determine whether CPX-1 is effective in patients with advanced colorectal cancer who have already received chemotherapy that included the drug oxaliplatin or irinotecan. All patients will receive CPX-1 at a dose of 210 units/m2 over 90 minutes every two weeks.
DISEASE(S): Colorectal Cancer,Colorectal Neoplasms
PROVIDER: 2031592 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA